Norris Perne & French LLP MI Has $8.74 Million Position in NuVasive, Inc. (NASDAQ:NUVA)

Norris Perne & French LLP MI raised its stake in shares of NuVasive, Inc. (NASDAQ:NUVA) by 60.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 113,660 shares of the medical device company’s stock after buying an additional 42,625 shares during the period. NuVasive accounts for approximately 1.5% of Norris Perne & French LLP MI’s portfolio, making the stock its 23rd largest position. Norris Perne & French LLP MI’s holdings in NuVasive were worth $8,743,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Capstone Asset Management Co. boosted its stake in NuVasive by 14.2% in the first quarter. Capstone Asset Management Co. now owns 8,196 shares of the medical device company’s stock valued at $612,000 after buying an additional 1,017 shares in the last quarter. Campbell Newman Asset Management Inc. boosted its stake in NuVasive by 14.1% in the first quarter. Campbell Newman Asset Management Inc. now owns 3,459 shares of the medical device company’s stock valued at $258,000 after buying an additional 427 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in NuVasive by 3.2% in the first quarter. Louisiana State Employees Retirement System now owns 12,800 shares of the medical device company’s stock valued at $956,000 after buying an additional 400 shares in the last quarter. Columbus Circle Investors boosted its stake in NuVasive by 7.9% in the first quarter. Columbus Circle Investors now owns 745,483 shares of the medical device company’s stock valued at $55,673,000 after buying an additional 54,291 shares in the last quarter. Finally, Retirement Systems of Alabama boosted its stake in NuVasive by 0.3% in the first quarter. Retirement Systems of Alabama now owns 93,023 shares of the medical device company’s stock valued at $6,947,000 after buying an additional 307 shares in the last quarter.

Shares of NuVasive, Inc. (NASDAQ NUVA) opened at 65.79 on Monday. NuVasive, Inc. has a 1-year low of $56.70 and a 1-year high of $81.68. The company has a market capitalization of $3.34 billion, a price-to-earnings ratio of 103.61 and a beta of 1.06. The stock’s 50 day moving average price is $76.85 and its 200 day moving average price is $74.43.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The firm had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $261.95 million. During the same quarter in the previous year, the company posted $0.40 EPS. NuVasive’s revenue was up 10.3% on a year-over-year basis. Analysts expect that NuVasive, Inc. will post $2.00 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was reported by [[site]] and is the property of of [[site]]. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at [[permalink]].

Several analysts recently commented on NUVA shares. BMO Capital Markets restated a “buy” rating and issued a $82.00 target price on shares of NuVasive in a research report on Tuesday, April 11th. Barclays PLC raised their target price on NuVasive from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Monday, April 24th. Canaccord Genuity restated a “buy” rating and issued a $84.00 target price (up from $82.00) on shares of NuVasive in a research report on Wednesday, April 26th. Zacks Investment Research raised NuVasive from a “sell” rating to a “hold” rating in a research note on Thursday, April 27th. Finally, TheStreet raised NuVasive from a “c+” rating to a “b” rating in a research note on Wednesday, May 3rd. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $81.18.

In other NuVasive news, EVP Peter Michael Leddy bought 7,850 shares of the stock in a transaction on Tuesday, August 1st. The stock was purchased at an average price of $63.88 per share, with a total value of $501,458.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 4.70% of the company’s stock.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).